Prior authorisation: difference between revisions
Diff·revision 16 → 17·07:03, 21 Jul 2025
Difference between revision 16 and revision 17 of Prior authorisation. 6 lines changed; the page grew by 564 bytes.
| Revision 16 — 09:37, 1 Jul 2025 PatientPanelPru (talk) state that the pricing data is self-reported where it is 3,517 bytes ±0 | Revision 17 — 07:03, 21 Jul 2025 SurvodutideSaff (talk) correct the annual cost — the source gives it per month 4,081 bytes +564 | ||
|---|---|---|---|
| 33 | That is a description of an observed pattern, not an endorsement of it. Research-use compounds are not approved for human administration.{{r|usp1503}} | 33 | That is a description of an observed pattern, not an endorsement of it. Research-use compounds are not approved for human administration.{{r|usp1503}} |
| 34 | 34 | ||
| + | 35 | == Variation == | |
| + | 36 | Prior authorisation is a feature of insurance-based systems and is largely absent where medicines are supplied through a national formulary, which uses different mechanisms — inclusion decisions, prescribing criteria, and volume controls — to the same cost-containment end. See [[Formulary tier]].{{r|ada2024}} | |
| + | 37 | ||
| + | 38 | Coverage of weight-management indications differs from coverage of diabetes indications for the same molecule in many systems, so status can depend on the indication rather than the drug.{{r|kyle2021}} | |
| + | 39 | ||
| 35 | == References == | 40 | == References == |
| 36 | {{reflist}} | 41 | {{reflist}} |
| ⋮ | ⋮ | ||
| 45 | * [[Cost per milligram]] | 50 | * [[Cost per milligram]] |
| 46 | * [[Global access disparity]] | 51 | * [[Global access disparity]] |
| + | 52 | * [[Telehealth prescribing]] | |
| 47 | 53 | ||
| 48 | {{DEFAULTSORT:Prior authorisation}} | 54 | {{DEFAULTSORT:Prior authorisation}} |